SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026)
SAB Biotherapeutics (SABS) reported Income from Continuing Operations of -$21.73 million for Q2 2026, compared with -$9.78 million a year earlier.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, SAB Biotherapeutics' Income from Continuing Operations came in at -$67.94 million; for FY2025, it was -$47.76 million.
- By year, Income from Continuing Operations came in at -$41.94 million in FY2024, -$42.19 million in FY2023, -$18.74 million in FY2022 and -$17.14 million in FY2021.
- The Q2 2026 figure ranks as the lowest quarterly Income from Continuing Operations since Q4 2023.
- Per Business Quant data, the three quarters before Q2 2026 came in at -$19.01 million (Q1 2026), -$15.13 million (Q4 2025) and -$12.07 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | SAB Biotherapeutics | 264.67 Mn | 264.67 Mn | - | -21.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.73 Mn |
| Mar 31, 2026 | -19.01 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -12.07 Mn |
| Jun 30, 2025 | -9.78 Mn |
| Mar 31, 2025 | -10.78 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
API Access
SAB Biotherapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();